CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01134575 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: CMC-544 (Inotuzumab Ozogamycin)
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]